Even With A 26% Surge, Cautious Investors Are Not Rewarding Genetic Signatures Limited's (ASX:GSS) Performance Completely
Nov 08
Have your own idea? Try our Stock Screener
Australian (ASX) Life Sciences Industry Analysis
UpdatedNov 14, 2025
DataAggregated Company Financials
Companies8
- 7D-1.9%
- 3M-4.4%
- 1Y-39.3%
- YTD-34.3%
Over the last 7 days, the Life Sciences industry has dropped 2.6%, driven by Trajan Group Holdings declining 12%. On the other hand Vitrafy Life Sciences is actually up 6.7%. The industry has fallen 39% in the last year. Earnings are forecast to grow by 55% annually.
Industry Valuation and Performance
Has the Australian Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 15 Nov 2025 | AU$525.7m | AU$273.6m | -AU$76,913,757.00 | 24.4x | -6.8x | 1.9x |
| Mon, 13 Oct 2025 | AU$521.2m | AU$273.6m | -AU$76,913,757.00 | 20.5x | -6.8x | 1.9x |
| Wed, 10 Sep 2025 | AU$503.2m | AU$273.6m | -AU$76,816,590.00 | 18.7x | -6.6x | 1.8x |
| Fri, 08 Aug 2025 | AU$558.6m | AU$273.7m | -AU$97,752,343.00 | 15.5x | -5.7x | 2x |
| Sun, 06 Jul 2025 | AU$434.6m | AU$272.6m | -AU$65,041,866.00 | 15.9x | -6.7x | 1.6x |
| Tue, 03 Jun 2025 | AU$412.8m | AU$272.6m | -AU$65,041,866.00 | 14x | -6.3x | 1.5x |
| Thu, 01 May 2025 | AU$395.7m | AU$272.6m | -AU$65,041,866.00 | 14.1x | -6.1x | 1.5x |
| Sat, 29 Mar 2025 | AU$462.3m | AU$272.6m | -AU$65,041,866.00 | 14.6x | -7.1x | 1.7x |
| Mon, 24 Feb 2025 | AU$488.2m | AU$254.0m | -AU$57,126,384.00 | 18x | -8.5x | 1.9x |
| Wed, 22 Jan 2025 | AU$550.5m | AU$253.8m | -AU$57,118,384.00 | 16.8x | -9.6x | 2.2x |
| Fri, 20 Dec 2024 | AU$596.1m | AU$263.5m | -AU$69,135,603.00 | 21x | -8.6x | 2.3x |
| Sun, 17 Nov 2024 | AU$643.7m | AU$263.5m | -AU$69,135,603.00 | 21.1x | -9.3x | 2.4x |
| Tue, 15 Oct 2024 | AU$716.3m | AU$263.5m | -AU$69,135,603.00 | 24.8x | -10.4x | 2.7x |
| Thu, 12 Sep 2024 | AU$679.3m | AU$263.3m | -AU$69,597,222.00 | 19.5x | -9.8x | 2.6x |
| Sat, 10 Aug 2024 | AU$617.7m | AU$246.1m | -AU$49,506,434.00 | 23.2x | -12.5x | 2.5x |
| Mon, 08 Jul 2024 | AU$595.1m | AU$246.1m | -AU$49,506,434.00 | 29.4x | -12x | 2.4x |
| Wed, 05 Jun 2024 | AU$541.7m | AU$246.1m | -AU$49,506,434.00 | 22.4x | -10.9x | 2.2x |
| Fri, 03 May 2024 | AU$537.5m | AU$246.1m | -AU$49,506,434.00 | 18.3x | -10.9x | 2.2x |
| Sun, 31 Mar 2024 | AU$540.5m | AU$246.1m | -AU$49,506,434.00 | 14.3x | -10.9x | 2.2x |
| Tue, 27 Feb 2024 | AU$512.2m | AU$243.2m | -AU$44,302,241.00 | 19.5x | -11.6x | 2.1x |
| Thu, 25 Jan 2024 | AU$467.1m | AU$248.2m | -AU$39,797,313.00 | 25.8x | -11.7x | 1.9x |
| Sat, 23 Dec 2023 | AU$527.1m | AU$248.6m | -AU$52,451,569.00 | 21.1x | -10x | 2.1x |
| Mon, 20 Nov 2023 | AU$543.8m | AU$248.6m | -AU$52,451,569.00 | 22.3x | -10.4x | 2.2x |
| Wed, 18 Oct 2023 | AU$557.2m | AU$248.6m | -AU$52,451,569.00 | 22.3x | -10.6x | 2.2x |
| Fri, 15 Sep 2023 | AU$573.0m | AU$248.6m | -AU$52,451,569.00 | 22.7x | -10.9x | 2.3x |
| Sun, 13 Aug 2023 | AU$645.3m | AU$221.5m | -AU$37,611,177.00 | 25.2x | -17.2x | 2.9x |
| Tue, 11 Jul 2023 | AU$647.0m | AU$221.5m | -AU$37,611,177.00 | 25.2x | -17.2x | 2.9x |
| Thu, 08 Jun 2023 | AU$680.9m | AU$221.5m | -AU$37,611,177.00 | 23.6x | -18.1x | 3.1x |
| Sat, 06 May 2023 | AU$619.9m | AU$221.5m | -AU$37,611,177.00 | 29.4x | -16.5x | 2.8x |
| Mon, 03 Apr 2023 | AU$722.0m | AU$221.7m | -AU$39,169,534.00 | 30.2x | -18.4x | 3.3x |
| Wed, 01 Mar 2023 | AU$791.2m | AU$212.6m | -AU$39,544,213.00 | 30.8x | -20x | 3.7x |
| Fri, 27 Jan 2023 | AU$828.6m | AU$184.6m | -AU$29,264,632.00 | 36.6x | -28.3x | 4.5x |
| Sun, 25 Dec 2022 | AU$776.6m | AU$184.6m | -AU$29,264,632.00 | 33.6x | -26.5x | 4.2x |
| Tue, 22 Nov 2022 | AU$759.7m | AU$184.6m | -AU$29,264,632.00 | 30.5x | -26x | 4.1x |
Price to Earnings Ratio
-26x
Current Industry PE
- Investors are pessimistic on the Australian Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 2.5x is higher than the industry's current PS ratio of 2.0x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 14% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Australian Healthcare industry?
| AU Market | -1.55% | |
| Healthcare | -0.74% | |
| Life Sciences | -1.95% | |
| Clinical Research and Equipment | -1.95% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| VFY Vitrafy Life Sciences | AU$1.60 | 6.7% +AU$6.4m | n/a | PS97.5x | |
| EZZ EZZ Life Science Holdings | AU$2.44 | 0.8% +AU$943.5k | -17.3% | PE17.1x | |
| MEM Memphasys | AU$0.004 | 0% AU$855.2k | -20.0% | PS18.6x |
